# uniQure N.V. (QURE) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $44.50, market value $3.1 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). uniQure N.V. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 165.3×**. Each dollar of revenue is priced at 165.3×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 9.5×**. The shares trade at 9.5× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -5.2%** (5-yr avg -13.9%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -100.0%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -90.4%**. Return on all capital, debt included, is -90.4%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -30.6%**. Each dollar of assets produces -30.6% of profit.

## Growth
- **Revenue growth (1 yr): -40.6%** (3-yr -46.7%/yr, 5-yr -15.6%/yr). Revenue fell 40.6% over the last year, against -15.6% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 29.7%**. Earnings per share rose 29.7%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.25**. Debt is 0.25 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.2×**. It would take 0.2 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 2.57**. A Z-score of 2.57 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. uniQure N.V. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (12 analysts). 12 analysts cover uniQure N.V.; the consensus is strong_buy, with an average price target of $69.70 (+57% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 151.0%** (YTD 86.0%, 3-mo 68.2%). The shares are up 151.0% over twelve months including dividends.
- **From 52-week high: -37.8%** (409.7% above the low). Trading 38% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 44**. An RSI of 44 is neutral.
- **Beta (1 yr): -0.27** (volatility 284%). Beta of -0.27 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=QURE · Page: https://foliofundamentals.com/stocks/qure

Not investment advice.